Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alimta in Relapsed Small Cell Lung Cancer
NCT00191750Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pemetrexed in small cell lung cancer (SCLC), sponsored by Eli Lilly and Company. Primary endpoints: Tumor Response Rate and Toxicities. Started Jul 2004; status: completed.
02
Drugs
pemetrexed
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00191750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191750.